中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 8
Aug.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(8): 1774-1779

Value of interleukin-6 combined with Model for End-Stage Liver Disease score in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2022.08.011

  • Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China

Research funding:

the National S & T Major Project (2017ZX10203201002-002);

Suzhou Youth Science and Technology Fund (KJXW2020003)

More Information
  • Corresponding author: GU Jing, 296326823@qq.com(ORCID: 0000-0002-7904-2793)
  • Received Date: 2021-10-21
  • Accepted Date: 2021-12-06
  • Published Date: 2022-08-20
    Abstract
  •   Objective  To investigate the value of interleukin-6 (IL-6) combined with Model for End-stage Liver Disease (MELD) score in predicting the prognosis of patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (HBV-ACLF).  Methods  A total of 86 patients with HBV-ACLF who were hospitalized in The First Affiliated Hospital of Soochow University from January 2015 to December 2018 were enrolled, and according to their survival status after follow-up for 90 days, they were divided into death group with 50 patients and survival group with 36 patients. ELISA was used to measure the serum level of IL-6, and a statistical analysis was performed for general information. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. A Pearson correlation analysis was performed for IL-6 and other variables; a binary logistic regression analysis was used to investigate the independent risk factors for the prognosis of patients with HBV-ACLF; the receiver operating characteristic (ROC) curve was used to assess the value of IL-6 combined with MELD score in predicting the prognosis of HBV-ACLF.  Results  There were significant differences between the death group and the survival group in hematocrit (t=2.413), platelet count (t=6.584), total bilirubin (TBil) (t=-8.070), prothrombin time (PT) (U=77.500), international standardized ratio (U=102.000), HBV DNA (t=-2.767), IL-6 (t=-16.543), and MELD score (t=-8.192), and the death group had a significantly higher level of IL-6 than the survival group (27.13±12.18 pg/mL vs 9.72±5.56 pg/mL, P < 0.001). The Pearson correlation analysis showed that IL-6 was positively correlated with TBil and PT (r=0.579 and 0.681, both P < 0.001). The binary logistic regression analysis showed that IL-6 (odds ratio[OR]=1.480, 95% confidence interval [CI]: 1.196~1.833, P=0.007) and MELD score (OR=1.128, 95%CI: 1.033~1.231, P < 0.001) were independent risk factors for the death of HBV-ACLF patients within 90 days. IL-6 combined with MELD score had an area under the ROC curve (AUC) of 0.891 (95%CI: 0.778~0.999), with a higher AUC than IL-6 (AUC=0.838, 95%CI: 0.687~0.989) or MELD score (AUC=0.783, 95%CI: 0.634~0.933). IL-6 combined with MELD score had a significantly higher value than IL-6 alone in predicting the prognosis of patients with HBV-ACLF (Z=-2.257, P=0.024).  Conclusion  IL-6 combined with MELD score can be used as a good model for predicting the short-term prognosis of patients with HBV-ACLF.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [2]
    YU XD, QIAN YB, HANG HL, et al. Research progress in acute-on-chronic liver failure[J]. Int J Dig Dis, 2019, 39(4): 252-255. DOI: 10.3969/j.issn.1673-534X.2019.04.004.

    俞旭东, 钱永兵, 杭化莲, 等. 慢加急性肝衰竭的研究进展[J]. 国际消化病杂志, 2019, 39(4): 252-255. DOI: 10.3969/j.issn.1673-534X.2019.04.004.
    [3]
    ZHOU C, ZHANG N, HE TT, et al. High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure[J]. World J Gastroenterol, 2020, 26(30): 4479-4488. DOI: 10.3748/wjg.v26.i30.4479.
    [4]
    YAN H, WU W, YANG Y, et al. A novel integrated Model for End-Stage Liver Disease model predicts short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure patients[J]. Hepatol Res, 2015, 45(4): 405-414. DOI: 10.1111/hepr.12362.
    [5]
    CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
    [6]
    SARIN SK, CHOUDHURY A. Acute-on-chronic liver failure: terminology, mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(3): 131-149. DOI: 10.1038/nrgastro.2015.219.
    [7]
    MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144(7): 1426-1437, 1437. e1-9. DOI: 10.1053/j.gastro.2013.02.042.
    [8]
    MIRZARAHIMI M, BARAK M, ESLAMI A, et al. The role of interleukin-6 in the early diagnosis of sepsis in premature infants[J]. Pediatr Rep, 2017, 9(3): 7305. DOI: 10.4081/pr.2017.7305.
    [9]
    WU W, YAN H, ZHAO H, et al. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: Differentiate it from No-ACLF[J]. Liver Int, 2018, 38(2): 248-257. DOI: 10.1111/liv.13504.
    [10]
    REMMLER J, SCHNEIDER C, TREUNER-KAUEROFF T, et al. Increased level of interleukin 6 associates with increased 90- day and 1-year mortality in patients with end-stage liver disease[J]. Clin Gastroenterol Hepatol, 2018, 16(5): 730-737. DOI: 10.1016/j.cgh.2017.09.017.
    [11]
    ABDALLAH MA, WALEED M, BELL MG, et al. Systematic review with meta-analysis: liver transplant provides survival benefit in patients with acute on chronic liver failure[J]. Aliment Pharmacol Ther, 2020, 52(2): 222-232. DOI: 10.1111/apt.15793.
    [12]
    JIA YN, LI H, LI XL, et al. Clinical progress of diagnostic and evaluation criteria for liver transplantation in patients with severe liver disease[J]. Ogran Transplant, 2020, 11(3): 326-331, 368. DOI: 10.3969/j.issn.1674-7445.2020.03.002.

    贾亚男, 李瀚, 李先亮, 等. 危重症肝病肝移植患者诊断和评估标准的临床进展[J]. 器官移植, 2020, 11(3): 326-331, 368. DOI: 10.3969/j.issn.1674-7445.2020.03.002.
    [13]
    LI H, ZHENG J, CHEN L, et al. The scoring systems in predicting short-term outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Ann Palliat Med, 2020, 9(5): 3048-3058. DOI: 10.21037/apm-20-608.
    [14]
    ZHU HJ, WAN J, SUN LN, et al. The early warning value of WBC, IL-6 and NLR in patients with acute-on- chronic liver failure[J]. Chin Hepatol, 2019, 2019, 24(9): 1076-1078. DOI: 10.3969/j.issn.1008-1704.2019.09.034.

    诸海军, 万健, 孙莲娜, 等. WBC、IL-6及NLR值对慢加急性肝衰竭患者的早期预警价值[J]. 肝脏, 2019, 24(9): 1076-1078. DOI: 10.3969/j.issn.1008-1704.2019.09.034.
    [15]
    WU CX, ZOU MY, ZHU YG. Value of serum IL-32, IL-6 and IL-8 in predicting prognosis of patients with acute-on-chronic liver failure by hepatitis B virus[J]. Jiangsu Med J, 2015, 41(23): 2847-2850. https://www.cnki.com.cn/Article/CJFDTOTAL-YIYA201523021.htm

    吴丛霞, 邹美银, 朱勇根. 血清IL-32、IL-6和IL-8水平预测慢加急性乙型肝炎肝衰竭患者预后的价值[J]. 江苏医药, 2015, 41(23): 2847-2850. https://www.cnki.com.cn/Article/CJFDTOTAL-YIYA201523021.htm
    [16]
    ZHANG L, CHEN W, SHENG YJ, et al. Value of Model for End-Stage Liver Disease score combined with neutrophil-lymphocyte ratio in predicting the short-term prognosis of patients with HBV-related acute-on-chronic liver failure[J]. J Clin Hepatol, 2018, 34(3): 553-557. DOI: 10.3969/j.issn.1001-5256.2018.03.021.

    张丽, 陈文, 盛云健, 等. MELD评分联合中性粒细胞/淋巴细胞比值对HBV相关慢加急性肝衰竭短期预后的预测价值[J]. 临床肝胆病杂志, 2018, 34(3): 553-557. DOI: 10.3969/j.issn.1001-5256.2018.03.021.
    [17]
    GAO XY, CHEN L, GAN JH. Value of Model for End-Stage Liver Disease score combined with platelet-to-white blood cell ratio in predicting the prognosis of patients with hepatitis B virus-associated acute-on-chronic liver failure[J]. J Clin Hepatol, 2021, 37(5): 1070-1074. DOI: 10.3969/j.issn.1001-5256.2021.05.019.

    高心怡, 陈丽, 甘建和. MELD评分联合血小板/白细胞比值对HBV相关慢加急性肝衰竭患者预后的预测价值[J]. 临床肝胆病杂志, 2021, 37(5): 1070-1074. DOI: 10.3969/j.issn.1001-5256.2021.05.019.
    [18]
    KANG N, WANG YZ, WANG CK, et al. Clinical significance of PTAR, Child-Pugh and MELD score in predicting the occurence of acute-on-chronic liver failure in patients with cirrhosis[J]. Chin J Gastroenterol Hepatol, 2020, 29(10): 1171-1178. DOI: 10.3969/j.issn.1006-5709.2020.10.019.

    康宁, 王玉珍, 王存凯, 等. PTAR联合Child-Pugh及MELD评分对肝硬化患者发生慢加急性肝衰竭预测价值研究[J]. 胃肠病学和肝病学杂志, 2020, 29(10): 1171-1178. DOI: 10.3969/j.issn.1006-5709.2020.10.019.
    [19]
    YANG J, HUANG YH. Value of serum MMP-2, AFP and MELD score in prognosis assessment of patients with HBV-related acute on chronic liver failure[J]. J Clin Pathol Res, 2019, 39(8): 1648-1653. DOI: 10.3978/j.issn.2095-6959.2019.08.006.

    杨君, 黄洋辉. 血清MMP-2, AFP与MELD评分对HBV相关慢加急性肝衰竭患者预后的评估价值[J]. 临床与病理杂志, 2019, 39(8): 1648-1653. DOI: 10.3978/j.issn.2095-6959.2019.08.006.
    [20]
    ZOU QX, LIN FW, WANG Y, et al. Changes and clinical significance of serum IL-2R, IL-6 and TNF-α in elderly patients with COVID-19[J]. J Changchun Univ Chin Med, 2020, 36(4): 692-694. DOI: 10.13463/j.cnki.cczyy.2020.04.023.

    邹青旭, 林风武, 王岩, 等. 老年新型冠状病毒肺炎患者血清IL-2R、IL-6、TNF-α水平变化及临床意义[J]. 长春中医药大学学报, 2020, 36(4): 692-694. DOI: 10.13463/j.cnki.cczyy.2020.04.023.
    [21]
    GONÇALVES BP, FLAUZINO T, INOUE CJ, et al. IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease[J]. Int J Colorectal Dis, 2021, 36(2): 383-393. DOI: 10.1007/s00384-020-03743-3.
    [22]
    SCHMIDT-ARRAS D, ROSE-JOHN S. IL-6 pathway in the liver: From physiopathology to therapy[J]. J Hepatol, 2016, 64(6): 1403-1415. DOI: 10.1016/j.jhep.2016.02.004.
    [23]
    ZENG Y, PAN QB, REN H, et al. Neutralization of interleukin-6 alleviates acute liver injury in mice[J]. Chin J Hepatol, 2020, 28(6): 509-514. DOI: 10.3760/cma.j.cn501113-20200224-00066.

    曾怡, 潘青波, 任红, 等. 中和白细胞介素-6减轻小鼠急性肝损伤[J]. 中华肝脏病杂志, 2020, 28(6): 509-514. DOI: 10.3760/cma.j.cn501113-20200224-00066.
    [24]
    FAZEL MODARES N, POLZ R, HAGHIGHI F, et al. IL-6 trans-signaling controls liver regeneration after partial hepatectomy[J]. Hepatology, 2019, 70(6): 2075-2091. DOI: 10.1002/hep.30774.
    [25]
    KIM HY, JHUN JY, CHO ML, et al. Interleukin-6 upregulates Th17 response via mTOR/STAT3 pathway in acute-on-chronic hepatitis B liver failure[J]. J Gastroenterol, 2014, 49(8): 1264-1273. DOI: 10.1007/s00535-013-0891-1.
    [26]
    WANG LY, MENG QH, ZOU ZQ, et al. Increased frequency of circulating Th17 cells in acute-on-chronic hepatitis B liver failure[J]. Dig Dis Sci, 2012, 57(3): 667-674. DOI: 10.1007/s10620-011-1930-5.
    [27]
    ZHAI S, ZHANG L, DANG S, et al. The ratio of Th-17 to Treg cells is associated with survival of patients with acute-on-chronic hepatitis B liver failure[J]. Viral Immunol, 2011, 24(4): 303-310. DOI: 10.1089/vim.2010.0135.
    [28]
    NIU Y, LIU H, YIN D, et al. The balance between intrahepatic IL-17(+) T cells and Foxp3(+) regulatory T cells plays an important role in HBV-related end-stage liver disease[J]. BMC Immunol, 2011, 12: 47. DOI: 10.1186/1471-2172-12-47.
    [29]
    ZHOU C, ZHANG N, GONG M, et al. Study on the expression of IL-6 in patients with hepatitis B virus related acute on-chronic liver failure and its impact on prognosis[J]. Chin Hepatol, 2021, 26(1): 12-15. DOI: 10.3969/j.issn.1008-1704.2021.01.007.

    周超, 张宁, 宫嫚, 等. 乙型肝炎病毒相关慢加急性肝衰竭患者IL-6的表达及其对预后的影响[J]. 肝脏, 2021, 26(1): 12-15. DOI: 10.3969/j.issn.1008-1704.2021.01.007.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (410) PDF downloads(69) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return